10

15

20

What Is Claimed Is:

- 1. A mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprising the substitution of a neutral and/or hydrophobic amino acid for one or more of the following:
 - (a) Glutamate 89; or
 - (b) Aspartate 101; or
 - (c) Leucine 137.
- 2. The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Glu ⁸⁹.
- 3. The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Asp ¹⁰¹.
- 4. The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Leu ¹³⁷.
- 5. The mutein of claim 1 which comprises the substitution of a neutral amino acid for Glu 89.
- 6. The mutein of claim 1 which comprises the substitution of a neutral amino acid for Asp ¹⁰¹.
- 7. The mutein of claim 1 which comprises the substitution of a neutral amino acid for Leu ¹³⁷.
- 8. The mutein of claim 1 wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.
 - 9. The mutein of claim 1 which is human basic fibroblast growth factor [Ala ⁸⁹].

10

- 10. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 101].
- 11. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 137].
- 12. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 89, 101].
- 13. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 89, 137].
- 14. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 101, 137].
- 15. The mutein of claim 1 which is human basic fibroblast growth factor [Ala 89, 101, 137].
- 16. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr 89].
- 17. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr ¹⁰¹].
 - 18. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr ¹³⁷].
- 19. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr ^{89, 101}].

15

- 20. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr ^{89, 137}].
- 21. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr $^{101, 137}$].
- 22. The mutein of claim 1 which is human basic fibroblast growth factor [Tyr ^{89, 101, 137}].
 - 23. A polynucleotide encoding the mutein of claim 1.
 - 24. The polynucleotide of claim 23 which is DNA.
 - 25. The polynucleotide of claim 23 which is genomic DNA.
 - 26. The polynucleotide of claim 23 which is a cDNA.
 - 27. The polynucleotide of claim 23 which is RNA.
 - 28. A vector containing the DNA of claim 25.
 - 29. A vector containing the DNA of claim 26.
 - 30. A vector containing the RNA of claim 27.
 - 31. A host cell comprising the vector of claim 28.
 - 32. A host cell comprising the vector of claim 29.
 - 33. A host cell comprising the vector of claim 30.
 - 34. A process for producing a polypeptide comprising expressing from the host cell of claim 32 the polypeptide encoded by said DNA.

20

- 35. A process for producing a polypeptide comprising expressing from the host cell of claim 33 the polypeptide encoded by said DNA.
 - 36. A process for producing the vector of claim 28 which comprises:
 - (a) inserting the polynucleotide of claim 25 into the vector; and
 - (b) selecting and propagating said vector in a host cell.
 - 37. A process for producing the vector of claim 29 which comprises:
 - (a) inserting the polynucleotide of claim 26 into the vector; and
 - (b) selecting and propagating said vector in a host cell.
 - 38. A process for producing the vector of claim 30 which comprises:
- (a) creating a recombinant RNA molecule containing the RNA sequence of claim 27; and
 - (b) selecting and propagating said vector in a host cell.
 - 39. A method of stimulating cell division which comprises:
- (a) contacting cells with an effective amount of the mutein of claim 1 *in vitro*; or
- (b) contacting cells with an effective amount of the mutein of claim 1 *in vivo*.
- 40. A pharmacologic composition useful for stimulating cell division comprising the following:
- (a) An effective amount of the human basic fibroblast growth factor mutein of claim 1; and
 - (b) An acceptable pharmaceutical carrier.
- 41. A method of healing a wound comprising contacting said wound with an effective amount of the mutein of claim 1.

- 42. A method of treating ischemia comprising contacting cells with an effective amount of the mutein of claim 1.
- 43. A method of treating peripheral vascular disease comprising contacting cells with an effective amount of the mutein of claim 1.
- 44. A method of treating a neural injury comprising contacting cells with an effective amount of the mutein of claim 1.
- 45. A method of treating a gastric ulcer comprising contacting cells with an effective amount of the mutein of claim 1.
- 46. A method of treating a duodenal ulcer comprising contacting cells with an effective amount of the mutein of claim 1.
- 47. A method of treating heart disease comprising contacting cells with an effective amount of the mutein of claim 1.